Amicus Therapeutics
Pharmacological chaperone developer raises $55M in financing
Published in Lab Business Week, October 9th, 2005
The company intends to use the proceeds to advance its drug pipeline based on the company's unique technology that has the potential to transform the treatment of human genetic diseases. Amicus' lead compound Amigal (migalastat hydrochloride) is in a phase II clinical program for Fabry disease. All of Amicus' current investors participated in the Series C round, which was led by new investor Quaker BioVentures.
"Amicus has truly exciting technology that has breakthrough potential for the treatment of devastating genetic diseases," said Sherrill Neff, managing partner of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2005-10-09)
More Articles from Lab Business Week
- Access Pharmaceuticals
Targeted drug delivery company reports status of convertible notes - Alexion Pharmaceuticals, Inc.
Vikas Sinha named senior VP and CFO for cardiovascular drug maker - Algeta ASA
Cancer drug developer raises EUR 23 million in series A round - Anadys Pharmaceuticals
Pharmaceutical company names member to board of directors - Ascentia Biomedical Corp.
Cancer drug developer receives $1M funding commitment - AstraZeneca
Nexium maker pledges more than $1M and medicine to Katrina victims - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
